External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

Therapeutic outcomes of neoadjuvant and concurrent androgen‐deprivation therapy and intensity‐modulated radiation therapy with gold marker implantation for intermediate‐risk and high‐risk prostate cancer

“…The use of long-term hormone therapy in combination with conventional doses (65-70 Gy) of external beam radiation therapy has been shown to contribute to improved therapeutic outcomes in patients with localized prostate cancer, particularly those at high risk, whereas short-term neoadjuvant hormone therapy is believed to contribute to improved therapeutic outcomes in patients at moderate risk. [17][18][19][20][21][22][23][24] However, the evidence for these indications is based on radiation doses of 65-70 Gy, and the value of ADT in combination with !76 Gy radiation doses remains unclear. Opinions on this point are divided, as some studies have found no association between ADT and therapeutic outcomes of !76 Gy IMRT, whereas others have reported improved DMFS.…”

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

“…The standard of care is IMRT combined with long term ADT, as it results in better OS [69][70][71]. The combination is clearly better than EBRT or ADT monotherapy [72].…”

Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

“…With the development of reversible forms of medical castration, indications for androgen deprivation have been expanded to include nonmetastatic disease. [2][3][4] The introduction of prostate-specific antigen (PSA) testing into clinical practice in the early 1990s provided an objective evaluation of the efficacy of definitive treatment; biochemical failure became an accepted end point. The ability to diagnose early treatment failure created a clinical dilemma.…”